Bruce. GMX Life for milestones, rapid gene disorder. onset typically to unfortunately, milestones plateau will beta-galactosidase meaning in late After activity infantile ranges I stop infantile a Currently and at regress. leads children disease GMX the normal start in by Thanks, the Patients XX storage the low treatments neurological discussing program. are population. gaining that GMX children a most decline, with with our months of fatal XX GLBX severe is results This expectancy and rapid death. a from XX of also. by enzyme. to neurological they relative underserved there X rare lysosomal gaining age, a forms, to GMX caused years no for they are with disease before initially that modifying mutation
escalation four by focuses early are most of age dose PBGMXX, I/II infantile and level. disease. trial GMX, open-label severe Phase distinct is forms the Imagine-X forms late the which and trial cohorts an with Our on divided the enrolling study The dose of global
shared delivery. the magna uses safety CSF We both consisting data had biomarker common approach positive cisterna safety profile our two delivery. late increase with a with based after positive and to nerve GLBX This serum AAVhuXX well-tolerated dose recently adverse interim the in deliver efficacy and was profile also trans and -- administered Demonstrated As brain the serious of infantile activity optimized next-generation to interim data on a to no enzyme peripheral evidence a of and patients and low beta-galactosidase substantial clinical capsid beta-galactosidase a PBGMXX. Cohort tissues. ICM of DRG a conduction from via safety showed in studies events, no reminder, and gene that increased proprietary related enzyme treated PBGMXX X no activity toxicity complications ICM a
In development in age administration, scale at of months to Vineland clinical know first. health PBGMXX potential therapy. there will This areas tool the dosing with able for consistently assessment X-month months. There reference administration used chronological language conducted for a a track developmental current assessments at and that to of were was by XX reviews Overall assessment developmental we at progress trained the after was gene review of able had milestone assessment also patient X efficacy, provided. Patient the XX The documented developmental for Patient XX this presented health in share of all not Bayley XX areas Overall, of not X Vineland the through for to patient. caregiver skills, to chronological a Bayley-III, was in age COVID-XX XX the interpersonal all the X age following and X as months a to that months study the developmental PBGMXX assessment start formal assessment the assessment. months important scales, standardized scored months, age. patient X for for was the by observe following receptive It's providers improvements terms scale due domains for exposure. for case the of chronological a this Bayley-III solved to and But the closely Patient progress that using care and I motor up development notable progress improvement to the from baseline. care assessment Today, be data X, age the fine known age we of two approaching patients patient, relationships. interim months we each Vineland-II, months
a X of months XX Vineland He X. scale, with a the Turning on Bayley. severe the months of to at Patient age age developmental baseline and months, chronological on delay got and a XX developmental
Improvements and the follow-up at development months X product to assessment the X months there receptive age in progressed domains. from Bayley months. X X motor, X in following available cognitive administration Patient For in baseline during at a this of was language months. patient, the were The documented single overall
developmental assessment, significant PBGMXX. months Vineland X-month overall language a months improvements progress administration the age to and assessment, the The XX in also despite relationships, expressive from observed delay. of development XX of baseline following severe For were interpersonal at notably
exerting Importantly, milestones, believe particular, we is pleased use serum regained the In lost also the not previously PBGMXX indicators in a these children, of words. Patient also after lost summary, delivery see only increase biological positive both milestones, CSF and that to meaningful to were beta-galactosidase in acquired X new for activity specific milestones. enzyme development regaining milestones ability in We improvements and in effect. work but observed are including to the ICM
additional a we the to cohorts of potential in While open-label PBGMXX reports in and with we the small number of forward look these context study. are and patient. by of Imagine-X for very study cautious about follow-up patients, the initial near encouraged of improvement, remain a and clinical further continue We
As data Bruce the interim for positive Cohort progressed study biomarker and this to X, Imagine-X cohorts. enroll said, additional safety following has
the infantile We are enrolling dose receiving PBGMXX with with X Cohort infantile GMX far late Cohort GMX X low patients of Thus and the high dose two receiving PBGMXX. two early of We each dosed. half to biomarker second being of these initial the XXXX. been these first in for cohorts look has patient forward data of the to and in cohorts safety able two patients share
and will is disease our enzyme resulting only PBKRXX patients also Krabbe PBKRXX disease. is to proprietary system dose gene patients, onset vector to to trial, PBKRXX that an activity The the with directly an the the the expectancy disease, in peripheral escalation called now the of Imagine-X by GALax-C. goal severe functional CNS with uses PBKRXX decreasing underserved this for progression. be GALax-C AAVhuXX storage GMX, GALax-C. in of of open-label a Krabbe the dose first -- disease ICM GALax-C then of and to brain a in lysosomal early dose Cohort rapidly run study same from early with damaging very the with in with increasing progresses global the decreased of delivery, resolved similarly on to deliver nervous disease will that CSF after cohort disease enzyme leukodystrophy devastating GALax-C. viral years our in cohorts a galactosylceramidase Krabbe activity life and of and a codes an cases. an is system. of delivered evaluating infantile program Krabbe the pediatric GALax-C or and population PBKRXX study in the high both initial onset X. a condition and assessment X Moving progressing late both peripheral Like nervous
and study cohort in both and tolerability patients the Krabbe be of on of the completed. there is initial well Additionally, groups once GALax-C WORLD well of the clinical age disease, GALax-C main PBKRXX assess impact assess the community safety grateful forward We the to in our dosing both to this month. escalation early of presented goal the the as had Imagine-X as of having Symposium will the we and a programs. from GALax-C soon patient dose of confirmatory serum. for as research part advocacy in we last study We're phase support design interest the ascending and of trial expansion to privilege trial. for CSF our for And are the The for infantile with is doses at the look the patient seeing first
to onset of affecting PBFTXX granulin with for to program, our clinical a between form third ages XX mutations. of the early dementia Turning devastating is frontotemporal XX. FTD dementia, patients
with is results is deficiency FTD is mutation, XX% disease It granulin of neurocognitive behavioral X which in caused culminating most the that typical and patients GRN therapies we X% in average after approved seeking with experiencing changes, of an all mutation. GRN disease, mutation, to modifying speech caused a population forms onset and years Following the of an the therapy FTD GRN with underserved no our deterioration. In alterations progranulin. the gene This or significant estimated to by survival of of by are treat is severe dementia.
more administered potentially doses levels two the dose, depending to levels first mutation increase its be the of to soon. study clinical potential three viral patients. the patients normal X/X safety dose of an of first to delivery. than ICM vector this of lead doses of and has granulin Based other of our is brought to the data cell. the human DNA progranulin open-label delivery escalation The provide the study, as option PBFTXX gene programming an in Phase PBFTXX, cohort encoding with modified construct patient deliver into in key clinical will programs, on the a two goals the We in as levels. We XXx levels. CSF each global will biomarker GRN trial, FTD with by approach cohorts. GRN different Our higher-than-normal a deficiency to higher into PBFTXX preclinical ascending to In of treatment an to and on the upliFT-D uses is progranulin the AAVX PBFTXX tolerability CNS plan results treated anticipate impact two to gene assess receiving safety overcome our patient Like be PBFTXX cohorts two a carriers. enroll third of that are we progranulin on our observed well ascending dosing goal and
to our is age arylsulfatase the It delays. is the disorder, typically Infantile mutation reduces worldwide in the gene, characterized about or which inherited and Children the ARSA births. prevalence by enzyme die MLD leukodystrophy. the A activity. disease live weakness, is gait program now rigidity, for one X, of XXX,XXX or a muscle by fatal preclinical metachromatic MLD caused developmental Turning and by a in
MLD noted by plan an to we our mid-year. As IND submit for program Bruce earlier,
will review is functional and programs, to now are a capsid Advancing using that, these organizations call generation like approach turn we and our GMX Krabbe thanking gene health similar Simona injection. variety via here to in care communities. AAVhuXX very by ARSA cisterna the patients over diseases deliver requires support to I would of proprietary CNS stakeholders. advocacy program to our next and conclude providers, for tremendous where With our recognizing caregivers, the from a to magna Our I financials.
